Instrument Inactif

Communiqués OncoSec Medical Inc Nasdaq

Actions

US68234L2079

Recherche biotechnologique et médicale

Communiqués

14/06/23	OncoSec Medical Incorporated : Bankruptcy - Form 8-K	PU
02/06/23	ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
18/05/23	OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
16/05/23	OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
16/05/23	OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program	PR
27/04/23	ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/04/23	OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program	PR
11/04/23	ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/04/23	OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
10/04/23	OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
04/04/23	OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	AQ
03/04/23	ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/04/23	OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	PR
14/03/23	ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
22/02/23	ONCOSEC MEDICAL INC : Other Events (form 8-K)	AQ
04/01/23	ONCOSEC MEDICAL INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
28/12/22	ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
27/12/22	ONCOSEC MEDICAL INC : Change in Directors or Principal Officers (form 8-K)	AQ
15/12/22	ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
05/12/22	OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022	PR
01/12/22	ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
30/11/22	OncoSec Announces Pricing of $3.5 Million Public Offering	PR
29/11/22	ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/11/22	ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
15/11/22	OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma	PR